On November 8, 2013 Patrys reported that it has been granted a second US patent for lead anti-cancer product PAT-LM1 (Press release Patrys, NOV 8, 2013, View Source [SID:1234500547]).
The United States Patent Office has issued the official "Letters Patent" on a key patent in the PAT-LM1 family; US patent 8,562,995 entitled "Neoplasm specific antibodies and uses thereof". It offers patent protection through to March 2024.
This is the second patent to be granted in the US jurisdiction, and the third for the PAT-LM1 family. In June this year a patent covering the use of the PAT-LM1 antibody or binding fragments for the treatment or prevention of metastasis was granted in New Zealand.
The patent claims the PAT-LM1 antibody and other variants comprising the Complementary Determining Region (CDRs) of the PAT-LM1 antibody.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!